

7 March 2023

Biologic drugs used in Gastroenterology and Crohn's Disease

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira: 38
- Adalimumab Biosimilar: 330
- Filgotinib: 1
- Golimumab: 10
- Infliximab – Remicade + Infliximab Biosimilar: Combined total 270
- Ozanimmo: 0
- Tofacitinib: 8
- Upadacitinib: 4
- Ustekinumab: 160
- Vedolizumab: 170

Q2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Crohn's Disease ONLY with the following biologic drugs:

- Adalimumab – Humira: 30
- Adalimumab Biosimilar: 230
- Golimumab: 0
- Infliximab – Remicade + Infliximab Biosimilar: Combined total 180
- Upadacitinib: 0
- Ustekinumab: 155
- Vedolizumab: 75